REM Sleep Behavior Disorder Clinical Trial
Official title:
Familial Aggregation and Biomarkers in REM Sleep Behaviour Disorder: a Case-control Family Study
In this cohort study, the investigators aim to study the familial aggregation of REM sleep behavior disorder (RBD) and compare the differences in major biomarkers of neurodegeneration, including percentage of EMG activity during REM sleep, cognitive functions, autonomic dysfunction, and psychiatric disorders, between unaffected first degree relatives of RBD cases and non-RBD controls.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. Chinese aged 40 or above; 2. Being capable of giving informed consent for participation of the study; 3. Sex matched between relatives from probands and controls. Exclusion Criteria: 1. Aged 39 or below; 2. Not capable of giving informed consent for participation of the study |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The prevalence rate of probable RBD among first degree relatives of RBD probands | The prevalence rate of probable RBD based on the self-reported/proxy-reported RBD symptoms in RBDQ-HK among first degree relatives of RBD probands in comparison to that of first degree relatives of controls. | 15 minutes | |
Primary | The weighted prevalence rate of confirmed RBD among first degree relatives of RBD probands. | The weighted prevalence rate of first degree relatives meeting full ICSD-II2 diagnostic criteria for RBD confirmed by clinical history and vPSG. | one night (8 hours) | |
Secondary | The percentage of REM-related EMG activity (REMREEA) | The percentage of REM-related EMG activity (REMREEA) is the most reliable and valid marker in differentiating patients with RBD from normal controls. Basically, the REMREEA include two components, namely phasic EMG activity and tonic EMG activity, respectively. The phasic EMG events were defined as any burst of EMG activity lasting 0.1 to 5 sec with amplitude > 4 times the background EMG activity and will be score on the basis of 3-second mini-epoch during REM sleep. Each 30-sec epoch during REM sleep was scored as tonic or atonic depending on whether tonic chin EMG activity was present for more or less than 50% of the epoch. The total EMG activity was presented as the percentage of REM related EMG activity (REMREEA) with the percentage of tonic EMG activity plus the percentage of phasic EMG activity. | one night (8 hours) | |
Secondary | Significant motor activity | Significant motor activity were recorded by video-polysomnography. The motor analysis will be scored according to the previously established method. In view of the potential problem in inter-rater reliability in those mild motor activities, we will only include those complex activities and vocalizations in the analyses. It has been shown that there are large differences in the significant motor activities between patients with RBD and normal controls. In view of the relatively high night-to-night variability and low inter-rater reliability in scoring motor activity, it will be considered as secondary outcome. | one night (8 hours) | |
Secondary | Other biomarkers of RBD in the first degree relatives of RBD patients. | Previous studies have also confirmed that RBD patients present with autonomic dysfunction, olfactory dysfunction, color vision deficit, neurocognitive function, and a higher rate of psychiatric disorders, these markers will also be considered as secondary biomarkers and will be compared in the first degree relatives of between patients and controls. | 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03671772 -
Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
|
||
Recruiting |
NCT05109364 -
Terazosin and Parkinson's Disease Extension Study
|
Phase 2 | |
Recruiting |
NCT03288909 -
Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease
|
||
Completed |
NCT04006925 -
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
|
Phase 4 | |
Completed |
NCT03353207 -
Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
|
||
Completed |
NCT02824341 -
Exploration of the Reward System by Functional MRI in Parkinson's Disease Patients With and Without REM Sleep Behavior Disorder
|
N/A | |
Recruiting |
NCT03671798 -
Establish a National Registry of REM Sleep Behavior Disorder
|
||
Enrolling by invitation |
NCT01453127 -
DaTSCAN Imaging in Aging and Neurodegenerative Disease
|
Phase 4 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Completed |
NCT03595475 -
Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD
|
||
Completed |
NCT03255642 -
Efficacy and Safety of Melatonin and Clonazepam for IRBD
|
N/A | |
Recruiting |
NCT05904717 -
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06140511 -
DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER
|
||
Recruiting |
NCT04386317 -
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
|
Phase 2 | |
Enrolling by invitation |
NCT05514106 -
MIBG in Aging and Neurologic Disorders
|
Phase 4 | |
Completed |
NCT03645226 -
Gut Microbiota Across Early Stages of Synucleinopathy: From High-risk Relatives, REM Sleep Behavior Disorder to Early Parkinson's Disease
|
||
Recruiting |
NCT05262543 -
PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
|
||
Recruiting |
NCT04071899 -
French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP)
|
||
Recruiting |
NCT04048603 -
Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder
|
||
Completed |
NCT02708186 -
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
|
Phase 2 |